Shire
Shire is a biopharmaceutical company that develops therapeutics for rare diseases and also offers patient advocacy services.
Business Model:
Revenue: $15.2B
Employees: 10,001-999,999
Rankings
Industries / Tags:
Detailed Shire Information
Geographic Data
Address: Zählerweg 10
City: Zug
State: zug
Zip: 6300
Country: CH
Financial Info
Stage:
series unknown
Raised Last:
$0
Raised Total:$0
Social
Metrics
2,087,352Website Global Rank
9,948Website Monthly Traffic
Twitter Followers
Description
Shire is a biopharmaceutical company that develops therapeutics for rare diseases and also offers patient advocacy services.
Contact Phone:
Contact Email:
Shire went public on 1/10/2003 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
1/10/2003
Ticker Symbol:
SHPG
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2011 | Prexa | Series B | 7M |
| 5/2014 | Naurex | Series C | 0 |
| 3/2011 | Proclara Biosciences | Series B | 12.4M |
| 3/2012 | Promethera Biosciences | Series B | 0 |
| 11/2012 | ArmaGen Technologies | Series A | 0 |
| 10/2012 | Promedior | Series D | 0 |
| 11/2014 | Promethera Biosciences | Series C | 0 |
| 3/2014 | Proclara Biosciences | Series D | 0 |
| 5/2013 | Proclara Biosciences | Series C | 0 |
| 2/2018 | Rani Therapeutics | Venture Round | 0 |
| 3/2012 | Proclara Biosciences | Series B | 0 |
| 3/2012 | ENTEROME | Series A | 0 |
| 2/2018 | Rani Therapeutics | Venture Round | 0 |
| 11/2014 | Promethera Biosciences | Series C | 0 |
| 5/2014 | Naurex | Series C | 0 |
| 3/2014 | Proclara Biosciences | Series D | 0 |
| 5/2013 | Proclara Biosciences | Series C | 0 |
| 11/2012 | ArmaGen Technologies | Series A | 0 |
| 10/2012 | Promedior | Series D | 0 |
| 3/2012 | Promethera Biosciences | Series B | 0 |
| 3/2012 | ENTEROME | Series A | 0 |
| 3/2012 | Proclara Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/1987 | Venture Round | - | 1/1987 | Venture Round | - |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 1/2016 | Baxalta | |
| 11/2015 | Dyax | |
| 8/2015 | Foresight Biotherapeutics | |
| 2/2015 | Meritage Pharma | |
| 1/2015 | NPS Pharmaceuticals | |
| 5/2014 | Lumena Pharmaceuticals | |
| 5/2014 | Fibrotech Therapeutics | |
| 11/2013 | ViroPharma | |
| 3/2013 | SARcode Bioscience | |
| 3/2013 | Premacure |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
